NYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race

Shares of Pluristem Therapeutics Inc. (PSTI) rose over 11% on Wednesday, following positive data from the company's preclinical studies of PLX-PAD cells in the treatment of Duchenne muscular dystrophy.

from RTT - Biotech http://ift.tt/28QQps8
via IFTTT